Most-Downgraded StocksMost-DowngradedNASDAQ:PODD Insulet (PODD) Stock Forecast, Price & News $159.49 -4.37 (-2.67%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$158.84▼$164.1550-Day Range$154.67▼$284.2852-Week Range$152.43▼$335.91Volume928,177 shsAverage Volume826,692 shsMarket Capitalization$11.14 billionP/E Ratio179.20Dividend YieldN/APrice Target$281.93 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Insulet MarketRank™ ForecastAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside75.8% Upside$280.40 Price TargetShort InterestHealthy4.12% of Shares Sold ShortDividend StrengthN/ASustainability-1.20Upright™ Environmental ScoreNews Sentiment0.52Based on 12 Articles This WeekInsider TradingAcquiring Shares$1.01 M Bought Last QuarterProj. Earnings Growth31.71%From $1.64 to $2.16 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.07 out of 5 starsMedical Sector18th out of 972 stocksSurgical & Medical Instruments Industry3rd out of 101 stocks 4.3 Analyst's Opinion Consensus RatingInsulet has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 9 buy ratings, 7 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $280.40, Insulet has a forecasted upside of 75.8% from its current price of $159.49.Amount of Analyst CoverageInsulet has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.12% of the outstanding shares of Insulet have been sold short.Short Interest Ratio / Days to CoverInsulet has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Insulet has recently decreased by 13.51%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldInsulet does not currently pay a dividend.Dividend GrowthInsulet does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInsulet has received a 80.74% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Insulin pumps" product. See details.Environmental SustainabilityThe Environmental Impact score for Insulet is -1.20. Previous Next 2.5 News and Social Media Coverage News SentimentInsulet has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Insulet this week, compared to 6 articles on an average week.Search InterestOnly 14 people have searched for PODD on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.MarketBeat Follows9 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insulet insiders have bought 156.41% more of their company's stock than they have sold. Specifically, they have bought $1,006,994.00 in company stock and sold $392,721.00 in company stock.Percentage Held by InsidersOnly 0.90% of the stock of Insulet is held by insiders. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Insulet are expected to grow by 31.71% in the coming year, from $1.64 to $2.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insulet is 179.20, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 116.19.Price to Earnings Ratio vs. SectorThe P/E ratio of Insulet is 179.20, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 117.40.Price to Earnings Growth RatioInsulet has a PEG Ratio of 2.76. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioInsulet has a P/B Ratio of 23.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Insulet (NASDAQ:PODD) StockInsulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.Read More PODD Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PODD Stock News HeadlinesSeptember 29, 2023 | markets.businessinsider.com14 Analysts Have This to Say About InsuletSeptember 29, 2023 | finance.yahoo.comA Look At The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)September 29, 2023 | Porter and Company (Ad)Public Service Announcement: New National Emergency IncomingAmericans urged to share this new documentary with their friends and family before this looming event triggers a new national crisis… September 28, 2023 | finance.yahoo.comInsulet to Announce Third Quarter 2023 Financial Results on November 2, 2023September 27, 2023 | finance.yahoo.comInsulet Stock Begins to Show Signs of LifeSeptember 26, 2023 | finance.yahoo.comInsulet (PODD)'s True Worth: A Comprehensive Analysis of Its Market ValueSeptember 26, 2023 | forbes.comWill Insulet (PODD) Stock Recover To Its Pre-Inflation Shock Highs Of $300?September 26, 2023 | americanbankingnews.comInsulet Co. (NASDAQ:PODD) Receives Average Rating of "Moderate Buy" from AnalystsSeptember 29, 2023 | Porter and Company (Ad)Public Service Announcement: New National Emergency IncomingAmericans urged to share this new documentary with their friends and family before this looming event triggers a new national crisis… September 15, 2023 | finance.yahoo.comUnveiling Insulet (PODD)'s True Worth: Is It Really Priced Right?September 15, 2023 | finance.yahoo.comAt US$175, Is It Time To Put Insulet Corporation (NASDAQ:PODD) On Your Watch List?September 12, 2023 | morningstar.comInsulet Corp PODD Stock QuoteSeptember 12, 2023 | finance.yahoo.comInsulet (PODD) Expands Omnipod 5 Even As Macro Woes LingerSeptember 8, 2023 | finance.yahoo.comZacks Investment Ideas feature highlights: Workday, Energy Transfer and InsuletSeptember 7, 2023 | reuters.comInsulet shares slump on concerns of sales hit from new diabetes drugsSeptember 7, 2023 | fool.comWhy Insulet Stock Is Sinking TodaySeptember 6, 2023 | msn.comUBS Maintains Insulet (PODD) Neutral RecommendationSeptember 6, 2023 | markets.businessinsider.comWhat 12 Analyst Ratings Have To Say About InsuletSeptember 6, 2023 | finance.yahoo.comInsulet (PODD): A Hidden Gem in the Market? An In-Depth Analysis of Its ValuationSeptember 1, 2023 | finance.yahoo.comJames Hollingshead Bought 76% More Shares In InsuletAugust 31, 2023 | msn.comHP’s stock slumps on cautious outlook, VinFast shares on the move again and other stocks in the spotlightAugust 30, 2023 | finance.yahoo.comWhy Insulet Stock Rocked the Market TodayAugust 30, 2023 | msn.comAmbarella, HP Inc., Box, Insulet, Sunrun, Nvidia, and More Stock Market MoversAugust 30, 2023 | benzinga.comPresident and CEO of Insulet Makes $1.01M BuyAugust 30, 2023 | seekingalpha.comInsulet gains amid winning TRO in dispute with EOFlow, CEO insider buyAugust 30, 2023 | finance.yahoo.comMarkets Extend Rally at Midday Following Jobs and GDP ReportsAugust 30, 2023 | finance.yahoo.comS&P 500 Gains and Losses Today: Index Rises a 4th-Straight Day After Jobs, GDP DataSee More Headlines Receive PODD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter. Email Address PODD Company Calendar Last Earnings8/08/2023Today9/29/2023Next Earnings (Confirmed)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:PODD CUSIP45784P10 CIK1145197 Webwww.insulet.com Phone(978) 600-7000Fax978-600-0120Employees2,600Year Founded2000Price Target and Rating Average Stock Price Forecast$280.40 High Stock Price Forecast$350.00 Low Stock Price Forecast$185.00 Forecasted Upside/Downside+77.1%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)$0.89 Trailing P/E Ratio178.90 Forward P/E Ratio97.09 P/E Growth2.76Net Income$4.60 million Net Margins4.29% Pretax Margin4.76% Return on Equity22.42% Return on Assets4.83% Debt Debt-to-Equity Ratio2.47 Current Ratio3.34 Quick Ratio2.38 Sales & Book Value Annual Sales$1.31 billion Price / Sales8.52 Cash Flow$2.19 per share Price / Cash Flow72.78 Book Value$6.86 per share Price / Book23.21Miscellaneous Outstanding Shares69,820,000Free Float69,193,000Market Cap$11.12 billion OptionableOptionable Beta0.81 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. James R. Hollingshead Ph.D. (Age 60)Pres, CEO & Director Comp: $2.18MMr. Wayde D. McMillan (Age 52)Exec. VP,CFO & Treasurer Comp: $1.15MMs. Shacey Petrovic (Age 49)Director & Advisor Comp: $2.96MMr. Eric Benjamin (Age 40)Exec. VP, Chief Product & Customer Experience Officer Comp: $947.57kMr. Prem Singh (Age 46)Sr. VP of Global Operations Ms. Lauren BuddenVP, Chief Accounting Officer & ControllerMr. Mark FieldSr. VP & CTOMs. Deborah R. Gordon CPA (Age 53)VP of Investor Relations Mr. John Wodick Kapples (Age 63)Sr. VP & Gen. Counsel Ms. Laetitia Cousin (Age 47)Sr. VP of Regulatory Affairs, Quality Assurance & Compliance More ExecutivesKey CompetitorsTeleflexNYSE:TFXGlobus MedicalNYSE:GMEDBaxter InternationalNYSE:BAXIntegra LifeSciencesNASDAQ:IARTDexComNASDAQ:DXCMView All CompetitorsInsiders & InstitutionsPrem SinghBought 1 shares on 9/19/2023Total: $168.92 ($168.92/share)Triatomic Management LPBought 510 shares on 9/7/2023Ownership: 0.013%Portside Wealth Group LLCBought 11,946 shares on 9/1/2023Ownership: 0.017%James HollingsheadBought 5,550 shares on 8/28/2023Total: $1.01 M ($181.41/share)Wolverine Trading LLCBought 1,500 shares on 8/23/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions PODD Stock - Frequently Asked Questions Should I buy or sell Insulet stock right now? 16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 7 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PODD shares. View PODD analyst ratings or view top-rated stocks. What is Insulet's stock price forecast for 2023? 16 analysts have issued twelve-month price objectives for Insulet's stock. Their PODD share price forecasts range from $185.00 to $350.00. On average, they predict the company's stock price to reach $280.40 in the next year. This suggests a possible upside of 76.1% from the stock's current price. View analysts price targets for PODD or view top-rated stocks among Wall Street analysts. How have PODD shares performed in 2023? Insulet's stock was trading at $294.39 at the beginning of 2023. Since then, PODD shares have decreased by 45.9% and is now trading at $159.22. View the best growth stocks for 2023 here. Are investors shorting Insulet? Insulet saw a decrease in short interest in September. As of September 15th, there was short interest totaling 2,880,000 shares, a decrease of 13.5% from the August 31st total of 3,330,000 shares. Based on an average trading volume of 1,020,000 shares, the days-to-cover ratio is presently 2.8 days. View Insulet's Short Interest. When is Insulet's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our PODD earnings forecast. How can I listen to Insulet's earnings call? Insulet will be holding an earnings conference call on Thursday, November 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Insulet's earnings last quarter? Insulet Co. (NASDAQ:PODD) announced its earnings results on Tuesday, August, 8th. The medical instruments supplier reported $0.38 EPS for the quarter, beating the consensus estimate of $0.24 by $0.14. The medical instruments supplier had revenue of $396.50 million for the quarter, compared to analysts' expectations of $383.97 million. Insulet had a trailing twelve-month return on equity of 22.42% and a net margin of 4.29%. What ETFs hold Insulet's stock? ETFs with the largest weight of Insulet (NASDAQ:PODD) stock in their portfolio include Fidelity Digital Health ETF (FDHT), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Goldman Sachs Future Health Care Equity ETF (GDOC), Invesco Focused Discovery Growth ETF (IVDG), Harbor Health Care ETF (MEDI), Fidelity Disruptive Medicine ETF (FMED), VictoryShares Nasdaq Next 50 ETF (QQQN) and Nuveen ESG Mid-Cap Growth ETF (NUMG). What guidance has Insulet issued on next quarter's earnings? Insulet issued an update on its third quarter 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $402.14 million-$412.37 million, compared to the consensus revenue estimate of $400.90 million. What is Shacey Petrovic's approval rating as Insulet's CEO? 61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Insulet own? Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD). What is Insulet's stock symbol? Insulet trades on the NASDAQ under the ticker symbol "PODD." How do I buy shares of Insulet? Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Insulet's stock price today? One share of PODD stock can currently be purchased for approximately $159.22. How much money does Insulet make? Insulet (NASDAQ:PODD) has a market capitalization of $11.12 billion and generates $1.31 billion in revenue each year. The medical instruments supplier earns $4.60 million in net income (profit) each year or $0.89 on an earnings per share basis. How many employees does Insulet have? The company employs 2,600 workers across the globe. How can I contact Insulet? Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for the company is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at ir@insulet.com, or via fax at 978-600-0120. This page (NASDAQ:PODD) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.